← Oncology Approval Tracker

FDA DECISION ·

Eribulin mesylate injection (first generic)

eribulin mesylate · Gland Pharma

First generic approvalFirst genericBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First generic of the referenced eribulin injection for metastatic breast cancer after at least two metastatic chemotherapy regimens, or for unresectable or metastatic liposarcoma after an anthracycline-containing regimen.

LAMPGEN ANALYSIS

Why it matters

The first generic approval applies to an IV cytotoxic drug used in two different later-line disease settings.

What research teams should watch

Reconcile chemotherapy history and verify product strength, renal and hepatic function and blood-count thresholds.

PRIMARY RECORDS

Sources